Similar articles

• Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: moxonidine and rilmenidine.

  van Zwieten PA. van Zwieten PA. J Hypertens. 1997 Feb;15(2):117-25. doi: 10.1097/00004872-199715020-00001. J Hypertens. 1997. PMID: 9469786 Review.
• The imidazoline receptor in control of blood pressure by clonidine and allied drugs.

  Reis DJ, Piletz JE. Reis DJ, et al. Am J Physiol. 1997 Nov;273(5):R1569-71. doi: 10.1152/ajpregu.1997.273.5.R1569. Am J Physiol. 1997. PMID: 9374795 Review.
• Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol.

  Reid JL, Panfilov V, MacPhee G, Elliott HL. Reid JL, et al. Ann N Y Acad Sci. 1995 Jul 12;763:673-8. doi: 10.1111/j.1749-6632.1995.tb32461.x. Ann N Y Acad Sci. 1995. PMID: 7677387 Review.
• Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine.

  Van Zwieten PA, Peters SL. Van Zwieten PA, et al. Ann N Y Acad Sci. 1999 Jun 21;881:420-9. doi: 10.1111/j.1749-6632.1999.tb09390.x. Ann N Y Acad Sci. 1999. PMID: 10415946 Review.
• Imidazoline receptor agonist drugs: a new approach to the treatment of systemic hypertension.

  Yu A, Frishman WH. Yu A, et al. J Clin Pharmacol. 1996 Feb;36(2):98-111. doi: 10.1002/j.1552-4604.1996.tb04174.x. J Clin Pharmacol. 1996. PMID: 8852385 Review.